Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 15/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26666445 | 0.91 | OPRM1 (0.68) | OPRM1OPRK1OPRL1OPRD1CHRM1 | |
| SCHEMBL28505346 | 0.86 | OPRM1 (0.47) | OPRM1OPRK1OPRL1CHRM1 | |
| SCHEMBL26666519 | 0.84 | OPRM1 (0.61) | OPRM1OPRK1OPRL1OPRD1CHRM1 | |
| SCHEMBL26666521 | 0.83 | OPRM1 (0.67) | OPRM1OPRK1OPRL1OPRD1CHRM1 | |
| SCHEMBL4306275 | 0.83 | CHRM1 (0.57) | OPRM1OPRL1CHRM1DRD2 | |
| SCHEMBL30870578 | 0.83 | OPRM1 (0.44) | OPRM1OPRK1OPRL1CHRM1 | |
| SCHEMBL3243793 | 0.83 | HSD11B1 (0.53) | OPRM1CHRM1DRD2HTR2AHTR2C | |
| SCHEMBL30825657 | 0.83 | OPRM1 (0.46) | OPRM1OPRK1OPRL1CHRM1DRD2 | |
| SCHEMBL4963517 | 0.83 | OPRM1 (0.52) | OPRM1OPRK1OPRD1CHRM1 | |
| SCHEMBL28506788 | 0.82 | OPRM1 (0.59) | OPRM1OPRK1OPRL1OPRD1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2025-06-24 | — | — | US | disclosed |
| US-20240391940-A1 | FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | GENEROS BIOPHARMA LTD. (GB) | 2024-11-28 | — | — | US | disclosed |
| US-20240287020-A1 | SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2024-08-29 | — | — | US | disclosed |
| US-11970474-B2 | Substituted benzodiazoles and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2024-04-30 | — | — | US | disclosed |
| CN-112074511-B | Substituted benzodiazoles and their use in therapy | 托马斯·黑勒戴药物研究基金会 | 2024-04-26 | — | — | CN | disclosed |
| EP-4234544-A1 | FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | Generos Biopharma Ltd. (KY) | 2023-08-30 | — | — | EP | disclosed |
| EP-4234544-A1 | FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | Generos Biopharma Ltd. (KY) | 2023-08-30 | — | — | EP | disclosed |
| CN-116457347-A | Compound containing condensed rings, application thereof and composition containing compound | 健艾仕生物医药有限公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-114478482-A | Compound containing condensed ring, application thereof and composition containing compound | 健艾仕生物医药有限公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2022083731-A1 | FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | 健艾仕生物医药有限公司 | 2022-04-28 | — | — | WO | disclosed |
| US-7205292-B2 | Piperidines containing a lactam ring and a quinolinone, benzimidazolone, quinazolinone or benzodiazepinone group, e.g. N-[3R,7R)-1-(Cyclopropylmethyl)-2-oxo-7-phenylazepan-3-yl]-4-(2-oxo-1,4-dihydroquinazolin-3 (2H-yl)piperidine-1-carboxamide; treating headaches, migraine headaches and cluster headaches | MERCK & CO., INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-7196079-B2 | Benzodiazepine CGRP receptor antagonists | MERCK & CO, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196079-B2 | Benzodiazepine CGRP receptor antagonists | MERCK & CO, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196079-B2 | Benzodiazepine CGRP receptor antagonists | MERCK & CO, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7164024-B2 | Muscarinic acetylcholine receptor antagonist; Parkinson's disease; dystonia; analgesics; irritable bowel syndrome | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-20060194783-A1 | Cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2006-08-31 | — | — | US | disclosed |
| US-20060148790-A1 | Benzodiazepine cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2006-07-06 | — | — | US | disclosed |
| US-20040147506-A1 | Benzimidazolone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1386920-A1 | BENZIMIDAZOLONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-02-04 | — | — | EP | disclosed |
| US-3996362-A | ANTIDEPRESSANTS, ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1976-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147506-A1 | Benzimidazolone derivatives | HRH2, CCKAR, HRH4 | OPRM1 55/4885OPRK1 32/4885OPRL1 165/4885 |
| US-20060194783-A1 | Cgrp receptor antagonists | BDKRB1, CCKBR, BDKRB2 | OPRM1 121/4885OPRK1 46/4885OPRL1 18/4885 |
| US-11970474-B2 | Substituted benzodiazoles and use thereof in therapy | XDH, CYP4X1, CYP11B2 | OPRM1 1598/4885OPRK1 1793/4885OPRL1 2104/4885 |
| US-20240287020-A1 | SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY | XDH, CYP11B2, CYP4X1 | OPRM1 1245/4885OPRK1 1368/4885OPRL1 1719/4885 |
| US-20240391940-A1 | FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | STAT5A, STAT5B, JAK2 | OPRM1 4582/4885OPRK1 4491/4885OPRL1 4718/4885 |
| US-20060148790-A1 | Benzodiazepine cgrp receptor antagonists | BDKRB1, CCKBR, BDKRB2 | OPRM1 74/4885OPRK1 13/4885OPRL1 12/4885 |
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | XDH, CYP11B2, CYP4X1 | OPRM1 1245/4885OPRK1 1368/4885OPRL1 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.